Medtronic’s Evolut displays superior clinical outcomes

Medtronic has recently announced superior results from a three-year study comparing the clinical outcomes of Medtronic’s Evolut and Edwards’ Sapien, the leading devices in the TAVR market. According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1%. Credit: JHVEPhoto / Shutterstock.com. Medtronic has recently announced superior results from a three-year head-to-head study comparing the clinical outcomes of Medtronic’s Evolut and Edwards’ Sapien, the leading devices in the transcatheter aortic valve replacement (TAVR) market. The SMall Annuli Randomized To Evolut or Sapien (SMART) trial was performed on…

Source: Medical Device Network